DR. Reddy's Laboratories, Inc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: DR. Reddy's Laboratories, Inc Pharmaceutical Import Records from India — 32 Products, $86.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

DR. Reddy's Laboratories, Inc — Pharmaceutical Importer Profile (2026) | 32 Products, $86.4M Trade | TransData Nexus

DR. Reddy's Laboratories, Inc

Pharmaceutical Importer · United States · Cardiovascular Focus · $86.4M Total Trade · DGFT Verified

DR. Reddy's Laboratories, Inc is a pharmaceutical importer based in United States with a total trade value of $86.4M across 32 products in 20 therapeutic categories. Based on 1,746 verified import shipments from Indian Customs (DGFT) records, DR. Reddy's Laboratories, Inc is the #1 buyer in 3 products including Ciprofloxacin, Dexamethasone, Ofloxacin. DR. Reddy's Laboratories, Inc sources from 1 verified Indian supplier, with Dr.reddy's Laboratories Limited accounting for 100.0% of imports.

DR. Reddy's Laboratories, Inc — Import Portfolio & Supplier Network

DR. Reddy's Laboratories, Inc import network — 32 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to DR. Reddy's Laboratories, Inc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Dr.reddy's Laboratories Limited	$6.8M	279	100.0%

DR. Reddy's Laboratories, Inc sources from 1 verified Indian supplier across 141 distinct formulations. The sourcing is highly concentrated — Dr.reddy's Laboratories Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does DR. Reddy's Laboratories, Inc Import?

Formulation	Value	Ships
Amilodipine and benazepril hydrochloridecapsules USP 10MG/40MG (40464 x 100 packs = 4046400 nos	$150.0K	3
Metoprolol succinate extended-release tablets USP 50 MG (19989 packs x 500's= 9994500 nos	$150.0K	3
Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension USP 7.5ML bottle (23280 nos	$150.0K	3
Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension USP 7.5ML bottle (23328 nos	$150.0K	3
Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension USP 7.5ML bottle (23376 nos	$150.0K	3
Ciprofloxacin 0.3% and dexamethasone 0.1% otic suspension USP 7.5ML bottle (45744 nos	$150.0K	3
Metoprolol succinate extended-release tablets USP 25MG (23911 x 500's = 11955500nos	$150.0K	3
Zoledronic acid injection 4MG/5ML	$149.7K	3
Atomoxetine capsules USP 40MG (57468 packs x 30's= 1724040 nos	$149.1K	3
Omeprazole delayed-release capsules usp20mg (14499 packs x 1000's =14499000 nos)	$142.2K	3
Metoprolol succinate extended-release tablets USP 100MG (7517 x 500's=3758500	$106.1K	3
Metoprolol succinate extended-release tablets USP 25 MG (11984 packs x 500 's= 5992000 nos	$102.9K	3
Omeprazole delayed-release capsules usp40mg (13749 packs x 500's = 6874500 nos	$97.8K	3
[reward item]sumatriptan tablets USP 100MG 27's (27 Pack)(27756x27 = 749412)	$94.2K	3
Amilodipine and benazepril hydrochloridecapsules USP 5MG/20MG (26832 x 100 packs = 2683200 nos	$89.9K	3

Import Portfolio — Top 30 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Metoprolol	Cardiovascular	$16.1M	322	1.4%	6
2	Omeprazole	Gastrointestinal	$15.5M	310	1.1%	10
3	Esomeprazole	Gastrointestinal	$5.3M	106	0.6%	11
4	Diclofenac	Analgesics & Antipyretics	$4.7M	93	1.3%	9
5	Valsartan	Cardiovascular	$4.6M	92	1.5%	11
6	Montelukast	Respiratory	$4.3M	86	1.4%	7
7	Sodium	Nutritional Supplements	$3.9M	78	1.1%	11
8	Fluoxetine	CNS & Psychiatric	$3.6M	73	1.0%	10
9	Ciprofloxacin	Antibiotics	$3.0M	61	0.4%	1
10	Dexamethasone	Corticosteroids	$3.0M	61	0.7%	1
11	Ofloxacin	Advanced Antibiotics	$2.9M	57	0.4%	1
12	Tacrolimus	Immunosuppressants	$2.8M	56	0.7%	14
13	Fluconazole	Antifungals	$2.6M	63	1.8%	6
14	Magnesium	Vitamins & Supplements	$2.5M	51	0.7%	17
15	Clopidogrel	Cardiovascular	$2.4M	47	0.5%	16
16	Naproxen	Analgesics & Antipyretics	$2.1M	42	0.9%	8
17	Ras	Ayurvedic & Herbal Products	$1.8M	35	0.6%	8
18	Levofloxacin	Antibiotics	$965.3K	21	1.3%	12
19	Famotidine	Gastrointestinal	$890.9K	23	1.6%	9
20	Enalapril	Cardiovascular	$350.0K	7	0.1%	10
21	Fexofenadine	Antihistamines & Allergy	$350.0K	7	0.3%	14
22	Sirolimus	Immunosuppressants	$350.0K	7	2.3%	3
23	Capecitabine	Advanced Oncology	$300.0K	6	0.3%	17
24	Dasatinib	Advanced Oncology	$300.0K	6	1.8%	5
25	Doxorubicin	Oncology	$300.0K	6	0.4%	9
26	Glimepiride	Diabetes & Endocrine	$300.0K	6	0.4%	8
27	Ephedrine	Respiratory & OTC	$250.0K	5	1.1%	7
28	Ertapenem	Advanced Antibiotics	$250.0K	5	0.2%	17
29	Fulvestrant	Advanced Oncology	$250.0K	5	1.0%	7
30	Colchicine	Lipid & Metabolism	$200.0K	4	0.9%	11

DR. Reddy's Laboratories, Inc imports 32 pharmaceutical products across 20 categories into United States totaling $86.4M. The company is the #1 buyer for 3 products: Ciprofloxacin, Dexamethasone, Ofloxacin.

DR. Reddy's Laboratories, Inc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Dr. Reddy's Laboratories, Inc. is a U.S.-based subsidiary of Dr. Reddy's Laboratories Limited, an Indian multinational pharmaceutical company headquartered in Hyderabad, India. Established in 1984, Dr. Reddy's Laboratories Limited has grown to become a significant player in the global pharmaceutical industry, offering a wide range of products, including generic drugs, active pharmaceutical ingredients (APIs), and over-the-counter medications.

In the United States, Dr. Reddy's Laboratories, Inc. operates as a pharmaceutical importer and distributor, focusing on providing affordable and high-quality generic medications to the U.S. market. The company's product portfolio spans various therapeutic categories, such as cardiovascular, gastrointestinal, pain management, oncology, anti-infectives, pediatrics, and dermatology. Dr. Reddy's Laboratories, Inc. offers these products in multiple forms, including tablets, capsules, injectables, and topical creams.

2Distribution Network

Dr. Reddy's Laboratories, Inc. maintains a robust distribution network across the United States to ensure efficient delivery of its pharmaceutical products. The company has established warehouse facilities in key locations, including East Brunswick, New Jersey, which serves as the U.S. headquarters. These strategically positioned warehouses enable Dr. Reddy's Laboratories, Inc. to effectively manage inventory and meet the demands of the U.S. market.

The company's logistics capabilities are designed to support a wide geographic coverage, ensuring timely and reliable distribution of its products nationwide. By leveraging its distribution network, Dr. Reddy's Laboratories, Inc. can efficiently supply a diverse range of pharmaceutical products to various healthcare providers, pharmacies, and hospitals across the United States.

3Industry Role

In the United States pharmaceutical supply chain, Dr. Reddy's Laboratories, Inc. functions primarily as a pharmaceutical importer and distributor. The company focuses on importing finished pharmaceutical formulations from its parent company in India and distributing them to various stakeholders within the U.S. healthcare system. This role positions Dr. Reddy's Laboratories, Inc. as a key player in enhancing access to affordable generic medications for U.S. patients.

By importing and distributing a wide array of generic drugs, Dr. Reddy's Laboratories, Inc. contributes to the diversification and competitiveness of the U.S. pharmaceutical market. The company's emphasis on quality and regulatory compliance ensures that its products meet the standards required by U.S. authorities, thereby supporting the overall integrity and reliability of the pharmaceutical supply chain.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — DR. Reddy's Laboratories, Inc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Dr. Reddy's Laboratories, Inc. imports finished pharmaceutical formulations exclusively from its parent company, Dr. Reddy's Laboratories Limited in India. This sourcing strategy results in a high supplier concentration, with a single supplier accounting for 100% of the imported products. Over the period from 2022 to 2026, the company imported a total of $86.4 million worth of products across 1,746 shipments, encompassing 32 different products across 20 therapeutic categories.

The top five imported products—Metoprolol, Omeprazole, Esomeprazole, Diclofenac, and Valsartan—collectively represent 53.4% of the total import value. This indicates a moderate level of portfolio concentration, with a significant portion of imports concentrated in these key products. The company's exclusive reliance on a single supplier may present risks related to supply chain disruptions, such as production delays or quality control issues. However, this sourcing strategy also allows for streamlined operations and potentially favorable pricing arrangements.

2Supply Chain Resilience

Dr. Reddy's Laboratories, Inc.'s supply chain resilience is closely tied to the operations of its parent company, Dr. Reddy's Laboratories Limited in India. The company's exclusive sourcing from a single supplier may limit its ability to diversify its supply chain and mitigate risks associated with potential disruptions. However, Dr. Reddy's Laboratories Limited has a strong manufacturing base and a history of compliance with international quality standards, which contributes to the overall reliability of the supply chain.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth the legal framework for drug imports, ensuring that all imported drugs meet the standards for quality, safety, and effectiveness.

Key legislation governing pharmaceutical imports includes the Drug Approval Process, which requires that drugs be proven safe and effective before they can be marketed in the U.S., and the Import for Export provisions, which allow certain unapproved drugs to be imported for further processing or incorporation into another product for subsequent export.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the U.S. mandate that all foreign drug establishments whose products are imported must register with the FDA and list all their drug products intended for commercial distribution in the United States. This process ensures that imported drugs meet FDA standards and are subject to the same regulations as domestic products.

Good Manufacturing Practice (GMP) certification is essential for imported pharmaceutical products. The FDA recognizes GMP certifications from various international bodies, including the European Union (EU) GMP, World Health Organization (WHO) GMP, and Pharmaceutical Inspection Co-operation Scheme (PIC/S). These certifications attest to the quality and safety of the manufacturing processes employed by foreign suppliers.

DR. Reddy's Laboratories, Inc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Dr. Reddy's Laboratories, Inc. focuses on importing and distributing a diverse range of generic pharmaceutical products across major therapeutic categories, including cardiovascular, gastrointestinal, pain management, oncology, anti-infectives, pediatrics, and dermatology. This strategic focus aligns with the company's mission to provide affordable and high-quality medications to the U.S. market.

The market demand for these therapeutic areas is driven by the prevalence of chronic conditions and the need for cost-effective treatment options. By offering generic versions of

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — DR. Reddy's Laboratories, Inc

What products does DR. Reddy's Laboratories, Inc import from India?

DR. Reddy's Laboratories, Inc imports 32 pharmaceutical products across 20 categories. Top imports: Metoprolol ($16.1M), Omeprazole ($15.5M), Esomeprazole ($5.3M), Diclofenac ($4.7M), Valsartan ($4.6M).

Who supplies pharmaceuticals to DR. Reddy's Laboratories, Inc from India?

DR. Reddy's Laboratories, Inc sources from 1 verified Indian suppliers. The primary supplier is Dr.reddy's Laboratories Limited (100.0% of imports, $6.8M).

What is DR. Reddy's Laboratories, Inc's total pharmaceutical import value?

DR. Reddy's Laboratories, Inc's total pharmaceutical import value from India is $86.4M, based on 1,746 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does DR. Reddy's Laboratories, Inc focus on?

DR. Reddy's Laboratories, Inc imports across 20 categories. The largest: Cardiovascular (27.1%), Gastrointestinal (25.1%), Analgesics & Antipyretics (7.8%).

Get Full DR. Reddy's Laboratories, Inc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 6 company name variants from customs records. For current shipment-level data, contact TransData Nexus.

DR. Reddy's Laboratories, Inc

DR. Reddy's Laboratories, Inc — Import Portfolio & Supplier Network

Who Are the Verified Indian Suppliers to DR. Reddy's Laboratories, Inc?

What Formulations Does DR. Reddy's Laboratories, Inc Import?

What Products Does DR. Reddy's Laboratories, Inc Import?

Top Products by Import Value

DR. Reddy's Laboratories, Inc Therapeutic Categories — 20 Specializations